Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Ferrous Sulfate

From Pharmacopedia
Revision as of 03:46, 23 May 2026 by MDElliottMD (talk | contribs) (parser-claude batch MedTemplate pre-fill, Top 300 #89)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Ferrous sulfate
Feosol, Fer-In-Sol, Slow Fe; mostly generic and OTC

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Common uses
Iron deficiency anemia0, Iron deficiency prevention (pregnancy, restricted diets, blood loss)0
Pharmacy
Starting dose
325 mg PO daily to TID (=65 mg elemental iron/tablet); alternate-day dosing is now favored by hepcidin physiology for better absorption with less GI burden
Preparations
325 mg tablets (65 mg elemental Fe); 220 mg/5 mL liquid (44 mg elemental Fe/5 mL); 142 mg/mL drops; OTC and Rx
US FDA Max
~200 mg elemental iron/d typical practical limit
Pharmacology
Routes
Oral
Onset
Reticulocyte response at 7-10 days; hemoglobin rise of ~1 g/dL per 3 weeks
Duration
N/A (replacement)
Half-life
N/A (incorporated into hemoglobin and tissue stores)
Bioavailability
10-20% (oral; reduced by food, calcium, antacids, PPIs, tea/coffee; enhanced by ascorbate)
Pregnancy
Routinely used; iron requirements rise substantially in pregnancy and lactation.[citation needed]
Legal status
OTC in US
Purported mechanism
Oral ferrous (Fe²⁺) iron is absorbed via DMT1 in the duodenum, transferred across enterocytes by ferroportin (regulated by hepcidin), and bound to plasma transferrin for delivery to bone marrow erythroblasts for hemoglobin synthesis.0 Replacement repletes both circulating hemoglobin iron and ferritin stores; treatment continues for 3-6 months after hemoglobin normalizes. Alternate-day dosing exploits hepcidin downregulation after a dose to improve fractional absorption while reducing constipation and nausea.

References